Company Investors Kamada Last week was surprised by a 20% increase in stock without notice from the company. The cause was probably Felix Prehn, a former hedge fund investor, poured into a financial influence on social networks, “Finfluencer.” Farhan posted a YouTube video reviewing a YouTube video that reviews Kamada, called “One stock that will turn a thousand dollars per million for you.” McMada said the incident also surprised them, and that they had no contact with pre -cow.
“Kamada’s story is just beginning,” Farhan said in the video. “But don’t buy shares just because someone on YouTube told you. It’s a biotch company that already makes money, and they have a huge agreement with a company in Latin America.” He noted for the plasma centers that the company has established as well as its gross profit and the fact that it has a variety of products and not just one. Finally, he noted the pricing, claiming that the market seems to have not yet discovered the company.
According to the initial results published in January for its annual report to 2024, the trend is indeed positive. The company is expected to report to 2024 for $ 158-162 million in revenue and EBITDA of $ 32-35 million, all according to expectation.
The company’s forecasts for 2025 $ 178-182 million, with EBITDA of $ 38-42 million, increase to 13% in revenue and 19% profit compared to 2024.
Even before the video was released, the company’s stock had already jumped about 10%this year, but the YouTube recommendation led to a stronger leap. And interesting that even after a week, the effect did not completely disappear.
The “Finfluencers”, financial influencers, most of which are not authorized investment advisers, have become a very important factor for the capital market. In a UK survey by the Berkelis financial services company, 23% of investors are influenced by content on social networks. The use of these channels is very age. The charges (60 and above) do not use networks at all and prefer to pay an expert advisor. The X generation and the millennial (30-60) used mainly in online forums and Facebook groups, while the Z generation, aged 30 and below, used mainly in Tiktok.
The same survey found that about 51% of those who use social media to receive investment recommendations do not examine the reliability of the influencer. When asked why they consume their investment tips precisely in this format, 26% stated that the information was available, 19% stated that they were accessing experts for free, while 19% claimed that in this way they were easier to digest the information. However, they are India that were happy that the platform, namely YouTube or Ticketok, will help them prevent fraud and improve transparency. Although it does not seem to happen in the near term.
Lord transfers most of its assets to a joint venture with a Chinese girlfriend
Company Torah Which has developed insulin pill in swallowing and trading in Tel Aviv and NASDAQ at a value of $ 89 million, is about to undergo a significant change: The company will transfer all insulin pill technology to a joint venture with its Chinese partner Hefei Tianhui Biotech Co. ORD will become a skeleton in part of the condemnation of shares. , In cash, and in a number of holdings in other biomed companies.
Following the announcement, Orem’s share has risen 12% in the last five days, and is traded at a value of $ 96 million.
Lorem develops drugs in the treatment of metabolic diseases, and its leading product is an insulin pill given in swallowing. Nadav Kidron, CEO of Orem, explains: “After the III phase of our clinical trials failed (an event that occurred in January 2023 and led to a decrease of 81% in one day), our partners actually succeeded in a parallel experiment in China. We saw that the Chinese experiment participants were a little different from those of the experiment we conducted, and indeed when we tested data in our experiment that were only taken from similar patients to those who participated in the Chinese experiment, we saw that the product was a success. This is not the whole market, but this is still a significant opportunity. “It should be noted that data analysis in retrospect is not considered a success of an experiment, so Olem has contacted FDA, in a proposal to conduct another stage III experiment, only in the target audience similar to the Chinese experiment.
Cadron: “In the meantime, the Chinese have invested hundreds of millions of dollars in factories that produce the entire value chain of our product for its launch in China, which we hope has happened this year.
As part of the agreement between the two companies, the technology of Ormed, including this product and other products in the company-related drug pipelines for metabolic disease, will be transferred to the joint venture, in which $ 75 million will be invested, of which about 60 million by Hefei Tianhui Biotech, and 15 million by 15 million Lord. Lord will hold most of the shares of the joint venture.
Following the move, Oremud’s shareholders will receive some of the company’s shares in the common venture as a dividend in the eye, and will continue to hold in Urmed, whose assets will be: the part of the shares of the joint venture that will not be divided as dividend; About $ 84 million in cash according to the last report, about 32 million that the SCILEX pain pharmaceutical company owed, which also holds in its non-traded shares, as well as a small amount of shares in the Antra-developed companies that develops drugs based on the technology of ORDA and traded Benask in the NASDAK on $ 89 million.
Anti -addictive amosfic: For the first time an experiment that shows this explicitly
The idea that drug reduction medication from the GLP1, such as Unusfek, works not only by intervention in the hunger and satiety mechanisms in the brain, but also in the mechanisms of desire and longing, is already known for anecdotal. On this basis, analysts have carefully estimated that the drug can be beneficial in the treatment of various addictions, besides obesity.
Now, the first clinical trial has set the test theory – and examined the effect of drugs on alcohol. This is a small experiment, and not controlled. It was conducted in 48 subjects who suffered from moderate alcohol addiction. A relatively low dose of unattopian for 9 weeks has significantly reduced alcohol consumption and the reported alcohol in a group that took the real drug compared to the dummy drug. At an event at the end of the 9 weeks to examine the durability of alcohol, the experimental group consumed 40% less than the dummy group. The results were published in the journal Jama Psychiatry.
Today there are two FDA-approved drugs, the US Food and Drug Administration, to treat alcohol addiction, but they are not considered particularly efficient and only about 2% of the diagnosed with the problem are accepted. The drugs are not so familiar to the market, and the stigma may also be blocked.
While the current experiment does not support the drug registration as a treatment of addiction, the two drug manufacturers for obesity from the GLP1 family, Novo Nordis andEli Lily We noted that they were planning to examine their pharmaceuticals in this (also mentioned expected experiments with cigarette and drug rehab.
The subjects suffered from the side effect of the drug and it is likely that, as in the case of the drug for obesity, it will be chronic when stopping the use of the drug may impair achievement. An interesting question is what will happen to a lean person to take the drug to wean alcohol. Is it beyond what it is, or when it comes to obesity that is not addictive or excess, should no medication this effect? This will have to check in their experiments.
Please note: The Globes system strives for a diverse, matter -of -fact and respectful discourse according to the ethical code that appears in the trust report by which we act. Expression of violence, racism, incitement or any other inappropriate discourse is filtered in a way Automatically And they will not be published on the site.
